|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Malignant neoplasm of pancreas
|
0.800 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of pancreas
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Pancreatic cancer is particularly resistant to apoptosis by antineoplastic agents, which is partly attributable to the lack of functional p53.
|
11585734 |
2001 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Trp53(+/-) mice overexpressing Tgfalpha in a pancreas-specific manner represent a well-established animal model for pancreatic cancer.
|
14506698 |
2003 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A combined approach targeting HDAC1/HDAC2 and MYC may present a novel and molecularly defined strategy to target mutant p53 in pancreatic cancer.
|
27721407 |
2017 |
|
Malignant neoplasm of pancreas
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
A trend toward an association of p53 overexpression with poorer survival was found in patients with pancreatic cancers of the same grade, stage or with the same immunophenotype, but the data did not reach statistical significance.
|
10076772 |
1998 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Accumulating evidence strongly suggests that p53 mutations contribute to the acquisition and/or maintenance of drug-resistant property of pancreatic cancer.
|
29558908 |
2018 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Activation of the proto-oncogene K-Ras and inactivation of the tumour suppressor gene loci INK4a, p53 and SMAD4 are characteristic for pancreatic cancer.
|
12079267 |
2002 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated p53 gene transfer suppressed growth of all human pancreatic cancer cell lines in a dose-dependent manner.
|
9869513 |
1998 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Advances in the understanding of pancreas cancer biology have been made over the past decade, including the discovery of critical mutations in oncogenes (i.e., K-Ras) as well as the loss of tumor suppressor genes, such as TP53 and p16(INK4).
|
16818496 |
2006 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Also in the light of the demonstrated cooperation of ras and p53 gene alterations in the transformation of cultured cells, our data suggest that p53 mutation is one of the genetic defects that may have a role in the pathogenesis of a proportion of pancreatic cancers.
|
8494051 |
1993 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Alterations in the p53 and Rb-1 genes may be important features in the development of human pancreatic cancer.
|
1630814 |
1992 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Although the rate of p53 mutations in pancreatic tumours is of the same order as in other adenocarcinomas (> or = 50%), an antibody response was found in only 5/78 (6.4%) sera from patients with pancreatic cancer.
|
7947080 |
1994 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Analysis by scanning electron microscopy revealed that these supernumerary structures are devoid of centrioles, a result significantly different from observations in aneuploid pancreatic cancer cell lines and in Trp53 or Brca1 deficient MEFs.
|
19768832 |
2009 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Based on these findings, trichodermin is a potential therapeutic agent worthy of further development into a clinical trial candidate for treating cancer, especially the mutant p53 pancreatic cancer.
|
27965041 |
2017 |
|
Malignant neoplasm of pancreas
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Both failed to specifically suppress p53 protein production in a cell-free assay system or to have any effect on mutant p53 expression by human pancreatic cancer cell lines.
|
7880719 |
1995 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Chromosomal rearrangements leading to gene disruption were prevalent, affecting genes known to be important in pancreatic cancer (TP53, SMAD4, CDKN2A, ARID1A and ROBO2) and new candidate drivers of pancreatic carcinogenesis (KDM6A and PREX2).
|
25719666 |
2015 |
|
Malignant neoplasm of pancreas
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer.
|
16127777 |
2005 |
|
Malignant neoplasm of pancreas
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.
|
12171884 |
2002 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
CTD_mouse |
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.
|
26390243 |
2015 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Comparing 3030 case patients with pancreatic cancer (43.2% female; 95.6% non-Hispanic white; mean age at diagnosis, 65.3 [SD, 10.7] years) with reference controls, significant associations were observed between pancreatic cancer and mutations in CDKN2A (0.3% of cases and 0.02% of controls; odds ratio [OR], 12.33; 95% CI, 5.43-25.61); TP53 (0.2% of cases and 0.02% of controls; OR, 6.70; 95% CI, 2.52-14.95); MLH1 (0.13% of cases and 0.02% of controls; OR, 6.66; 95% CI, 1.94-17.53); BRCA2 (1.9% of cases and 0.3% of controls; OR, 6.20; 95% CI, 4.62-8.17); ATM (2.3% of cases and 0.37% of controls; OR, 5.71; 95% CI, 4.38-7.33); and BRCA1 (0.6% of cases and 0.2% of controls; OR, 2.58; 95% CI, 1.54-4.05).
|
29922827 |
2018 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Concurrent loss of p53 and K-ras function may contribute to the clinical aggressiveness of pancreas cancer.
|
9219065 |
1997 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
DATS induces apoptosis of pancreatic cancer cells (Capan-2) and non-tumorigenic pancreatic ductal epithelial cells (H6C7).
|
24415872 |
2014 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Despite several potential advantages of stool testing for pancreatic cancer and its biological plausibility, only six studies investigating two genetic markers in stool (the K-ras and the p53 gene) could be identified.
|
18999925 |
2008 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Detection of K-ras mutation combined with p53 mutation in stool can aid in the screening of pancreatic cancer.
|
12609076 |
2002 |